BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Stock Fundamental Analysis

NASDAQ:BGMSP • US23254L2079

3.1 USD
-0.42 (-11.93%)
Last: Feb 20, 2026, 08:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

BGMSP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. BGMSP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BGMSP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • BGMSP had negative earnings in the past year.
  • BGMSP had a negative operating cash flow in the past year.
  • BGMSP had negative earnings in each of the past 5 years.
  • In the past 5 years BGMSP always reported negative operating cash flow.
BGMSP Yearly Net Income VS EBIT VS OCF VS FCFBGMSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • The Return On Assets of BGMSP (-85.49%) is worse than 70.06% of its industry peers.
  • BGMSP has a Return On Equity (-98.28%) which is in line with its industry peers.
Industry RankSector Rank
ROA -85.49%
ROE -98.28%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BGMSP Yearly ROA, ROE, ROICBGMSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BGMSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGMSP Yearly Profit, Operating, Gross MarginsBGMSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • BGMSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BGMSP has been increased compared to 1 year ago.
  • Compared to 5 years ago, BGMSP has more shares outstanding
  • BGMSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BGMSP Yearly Shares OutstandingBGMSP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
BGMSP Yearly Total Debt VS Total AssetsBGMSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • BGMSP has an Altman-Z score of -70.56. This is a bad value and indicates that BGMSP is not financially healthy and even has some risk of bankruptcy.
  • BGMSP has a Altman-Z score of -70.56. This is amonst the worse of the industry: BGMSP underperforms 92.51% of its industry peers.
  • There is no outstanding debt for BGMSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -70.56
ROIC/WACCN/A
WACC8.72%
BGMSP Yearly LT Debt VS Equity VS FCFBGMSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

  • BGMSP has a Current Ratio of 6.43. This indicates that BGMSP is financially healthy and has no problem in meeting its short term obligations.
  • BGMSP has a better Current ratio (6.43) than 65.45% of its industry peers.
  • BGMSP has a Quick Ratio of 5.07. This indicates that BGMSP is financially healthy and has no problem in meeting its short term obligations.
  • BGMSP's Quick ratio of 5.07 is in line compared to the rest of the industry. BGMSP outperforms 57.77% of its industry peers.
Industry RankSector Rank
Current Ratio 6.43
Quick Ratio 5.07
BGMSP Yearly Current Assets VS Current LiabilitesBGMSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 96.34% over the past year.
  • Looking at the last year, BGMSP shows a quite strong growth in Revenue. The Revenue has grown by 9.46% in the last year.
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%

3.2 Future

  • BGMSP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.16% yearly.
  • Based on estimates for the next years, BGMSP will show a very strong growth in Revenue. The Revenue will grow by 1049.89% on average per year.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A

3.3 Evolution

BGMSP Yearly Revenue VS EstimatesBGMSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2023 2024 2025 2026 2027 20M 40M 60M 80M
BGMSP Yearly EPS VS EstimatesBGMSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -100K -200K -300K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BGMSP. In the last year negative earnings were reported.
  • Also next year BGMSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGMSP Price Earnings VS Forward Price EarningsBGMSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGMSP Per share dataBGMSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BGMSP's earnings are expected to grow with 57.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • BGMSP has a Yearly Dividend Yield of 17.24%, which is a nice return.
  • The stock price of BGMSP dropped by -37.88% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • BGMSP's Dividend Yield is rather good when compared to the industry average which is at 1.17. BGMSP pays more dividend than 99.81% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.81, BGMSP pays a better dividend.
Industry RankSector Rank
Dividend Yield 17.24%

5.2 History

  • BGMSP has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr YearsN/A
Div Non Decr YearsN/A
BGMSP Yearly Dividends per shareBGMSP Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.1 0.2 0.3 0.4 0.5

5.3 Sustainability

DPN/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%
BGMSP Yearly Income VS Free CF VS DividendBGMSP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

More info and screens

Find the best dividend stocksShow peers with best dividend

BIO GREEN MED SOLUTION - BGMS 6 PERP

NASDAQ:BGMSP (2/20/2026, 8:18:38 PM)

3.1

-0.42 (-11.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-31
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners62.28%
Ins Owner ChangeN/A
Market Cap15.19M
Revenue(TTM)81.00K
Net Income(TTM)-6.97M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 17.24%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-Date01-22
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)58.82%
Min Revenue beat(2)-100%
Max Revenue beat(2)217.65%
Revenue beat(4)1
Avg Revenue beat(4)-20.59%
Min Revenue beat(4)-100%
Max Revenue beat(4)217.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 187.53
P/FCF N/A
P/OCF N/A
P/B 2.14
P/tB 2.75
EV/EBITDA N/A
EPS(TTM)-80.13
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.02
BVpS1.45
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.49%
ROE -98.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.43
Quick Ratio 5.07
Altman-Z -70.56
F-Score5
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A
EBIT growth 1Y40.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.9%
OCF growth 3YN/A
OCF growth 5YN/A

BIO GREEN MED SOLUTION - BGMS 6 PERP / BGMSP FAQ

What is the fundamental rating for BGMSP stock?

ChartMill assigns a fundamental rating of 3 / 10 to BGMSP.


Can you provide the valuation status for BIO GREEN MED SOLUTION - BGMS 6 PERP?

ChartMill assigns a valuation rating of 1 / 10 to BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP). This can be considered as Overvalued.


What is the profitability of BGMSP stock?

BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) has a profitability rating of 0 / 10.


What is the expected EPS growth for BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) stock?

The Earnings per Share (EPS) of BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) is expected to grow by 39.49% in the next year.